Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia

Pneumonia Clinical Trial

Official title:

A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Treatment of Patients With Severe Community-acquired Pneumonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00431678
• Other study ID #: 11215
• Status: Completed
• Phase: Phase 3
• First received: February 5, 2007
• Last updated: December 16, 2014
• Start date: January 2004
• Est. completion date: July 2005

Study information

• Verified date: December 2014
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

Sequential therapy with intravenous to oral moxifloxacin, was tested at 69 study centres in 17 countries to determine if this treatment regimen is safe and effective in treating hospitalized adult patients with community-acquired pneumonia. 748 patients were participated in the study over an 18 months period. Individual patient involvement in the study was approximately 4-6 weeks. Moxifloxacin was compared to a combination treatment regimen of high dose intravenous ceftriaxone plus high dose intravenous levofloxacin followed by high dose oral levofloxacin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 738
• Est. completion date: July 2005
• Est. primary completion date: July 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 18 years or above

• All of the following signs and symptoms of pneumonia:

• Fever (core/ rectal/ tympanic temperature >/= 38.5°C or axillary/ oral/ cutaneous temperature >/= 38.0°C) or hypothermia (core/ rectal/ tympanic temperature </= 35.5°C or axillary/ oral/ cutaneous temperature </= 35.0°C)

• White blood cell (WBC) count > 10,000/µL, or >/= 15% immature neutrophils (bands), regardless of the peripheral WBC count, or total WBC count < 4,500/µL

• The presence of at least 2 of the following symptoms: - Cough- Purulent sputum production

• Dyspnoea or tachypnoea (respiratory rate > 20 breaths/minute)

• Rigors and/or chills- Chest pain

• Auscultatory findings on pulmonary examination of rales/crackles and/or evidence of pulmonary consolidationAND

• Radiological evidence of (an) infiltrate(s) consistent with bacterial pneumonia at baseline or within 24 hours following enrolment

• Fine score >/= 71 (i.e. Pneumonia PSI risk Class III, IV or V, requiring hospitalisation for the treatment of CAP)

• Written informed consent obtained from the patient or a next-of-kin

Exclusion Criteria:

• Known hypersensitivity to fluoroquinolones, or other quinolones, and/or to beta-lactams, or any of the excipients

• Female patients who are pregnant or lactating

• History of tendon disease/disorder related to quinolone treatment

• Known congenital or documented-acquired QT prolongation; concomitant use of drugs, reported to increase the QT interval; uncorrected hypokalaemia; clinically relevant bradycardia; clinically relevant heart failure with reduced left

• ventricular ejection fraction; previous history of symptomatic arrhythmias

• History of epilepsy- Known glucose-6-phosphate dehydrogenase deficiency

• Known severe impaired liver function (i.e. Child Pugh C), (refer to Section 10.4 for definition) or transaminases increase > 5 fold ULN- Hospitalisation for > 48 hours before developing pneumonia, or discharge from hospital < 30 days prior- Systemic antibacterial therapy for more than 24 hours within 14 days of enrolment

• Patients requiring concomitant systemic antibacterial agents

• Known structural lung disease (e.g. cystic fibrosis, bronchiectasis, or lung cancer), or other known conditions (e.g. malnutrition) predisposing to infection with nosocomial-like organisms such as Pseudomonas aeruginosa

• Lung abscess, pleural empyema, risk factors for aspiration pneumonia (e.g. recent stroke, head injury, dementia)

• Known rapidly fatal underlying disease (death expected within 6 months)

• Known or suspected active tuberculosis or endemic fungal infection- Neutropenia (neutrophil count < 1,000/µL) caused by immunosuppressive therapy or malignancy

• Patients known to have AIDS (CD4 count < 200/µL) or HIV-seropositive patients receiving HAART

• Previous enrolment in this study

• Participation in any clinical investigational drug study within the previous 4 weeks

• Patient with pre-terminal renal failure (creatinine clearance < 10 mL/min) and patients undergoing haemodialysis

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pneumonia

Intervention

Drug:
• Avelox (Moxifloxacin, BAY12-8039)
Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
• Levofloxacin + Ceftriaxone
Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Argentina,  Belgium,  Chile,  Colombia,  France,  Germany,  Greece,  Israel,  Lithuania,  Mexico,  Netherlands,  Peru,  Poland,  Portugal,  South Africa,  Spain,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical response		5 to 7 days after last dose of study medication
Secondary	Clinical and bacteriological response		At the day of switch from intravenous to oral therapy
Secondary	Clinical and bacteriological response on treatment		At day 3 to 5
Secondary	Clinical and bacteriological response		At the end of treatment
Secondary	Bacteriological response		5-7 days after end of treatment
Secondary	Mortality attributable to pneumonia		5-7 days after end of treatment
Secondary	Clinical and bacteriological response		At days 21 to 28 after end of treatment
Secondary	Symptoms course of community-acquired pneumonia		at defined visits
Secondary	Adverse Event Collection		all visits

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer Healthcare products.